Results 251 to 260 of about 14,544 (270)

Aldose reductase inhibitors

2016
openaire   +1 more source

NTRK fusion-positive cancers and TRK inhibitor therapy

Nature Reviews Clinical Oncology, 2018
Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon   +2 more
exaly  

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Nature Reviews Cancer, 2019
Jonathan J Havel, Diego Chowell, Timothy A Chan   +2 more
exaly  

The nuclear export protein XPO1 — from biology to targeted therapy

Nature Reviews Clinical Oncology, 2020
Asfar S Azmi, Mohammed H Uddin, Ramzi M Mohammad   +2 more
exaly  

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

Nature Reviews Clinical Oncology, 2017
Mizuki Nishino, Hiroto Hatabu, F Stephen Hodi   +2 more
exaly  

Targeted agents and immunotherapies: optimizing outcomes in melanoma

Nature Reviews Clinical Oncology, 2017
Jason J Luke, Keith T Flaherty, Antoni Ribas   +2 more
exaly  

[Aldose reductase inhibitor].

Nihon rinsho. Japanese journal of clinical medicine, 2011
openaire   +1 more source

Irreversible aldose reductase inhibitors.

Progress in clinical and biological research, 1987
P F, Kador, R C, Gurley, J J, Ares, D D, Miller   +3 more
openaire   +1 more source

Appraising iniparib, the PARP inhibitor that never was—what must we learn?

Nature Reviews Clinical Oncology, 2013
Joaquin Mateo, Michael Ong, David S P Tan   +2 more
exaly  

Aldose reductase inhibitors—Hope or hype

Journal of Diabetes and its Complications, 1992
openaire   +2 more sources